About the Program
A therapeutic approach that uses modified RNA or DNA molecules that bind to the RNA of the UBE3A-ATS (UBE3A antisense transcript).
- FAST Pillar
- Pillar 2: Turn on Dad’s UBE3A
- Investigational Drug Name
- GTX-102
- Company Website
- Ultragenyx
- Drug Name
- apazunersen
Program History
In early 2012, FAST began funding Scott Dindot’s laboratory at Texas A&M University to understand the mechanism by which the UBE3A-antisense transcript (UBE3A-AS) silences the paternal UBE3A allele, why it is only silenced in neurons, and how that process may be leveraged as a potential therapy for AS. In late 2017, the Dindot laboratory identified an investigational ASO that, through preliminary studies, was shown to interfere with the imprinting mechanism of the paternal UBE3A allele in neurons, and unsilenced the gene. FAST wanted to ensure that the development of this program moved forward in the most expeditious, safe, and detailed manner possible, with the primary goal of moving into a human clinical trial if preclinical studies supported further investigation. To do this, FAST formed GeneTx Biotherapeutics LLC (GeneTx), a for-profit limited liability company, singularly focused to develop an investigational ASO for potential future use in a Phase 1/2 clinical trial for individuals living with AS.
In July 2022, GeneTX was sold to Ultragenyx Pharmaceuticals. Ultragenyx is now the sole Sponsor of the development program.
Scott DindotKey Researchers
Timeline:
FAST began funding Scott Dindot’s laboratory at Texas A&M University to understand the mechanism by which the UBE3A-antisense transcript (UBE3A-AS) silences the paternal UBE3A allele, why it is only silenced in neurons, and how that process may be leveraged as a potential therapy for AS.
the Dindot laboratory identified an investigational ASO that, through preliminary studies, was shown to interfere with the imprinting mechanism of the paternal UBE3A allele in neurons, and unsilenced the gene
FAST created a for-profit company called GeneTx Biotherapeutics LLC specifically for one purpose: to accelerate the development of an investigational antisense oligonucleotide drug for the potential treatment of AS.
the clinical trial was initiated, making this FAST-backed program the first potential disease-modifying therapy in human clinical trials for Angelman syndrome.
FAST announced that the company Ultragenyx Pharmaceuticals had exercised its option and closed on its acquisition of GeneTx Biotherapeutics LLC, a biotechnology company founded by FAST.

Questions about Clinical Trials?
Schedule a private, 1:1 appointment with Niki Armstrong, a genetic counselor who specializes in Angelman syndrome.
Meet with a Genetic CounselorMedia
▶Ultragenyx Community Webinar (2026)
▶GTX-102: What We’ve Learned Together (2025)
▶A GTX-102 Clinical Development Update: Results From the Phase 1/2 Open-Label Study and an Overview of the Pivotal Phase 3 Study (2024)
▶Update on Ultragenyx's Angelman Syndrome Aspire Trial (2024)
▶Update on the GTX-102 program for Angelman Syndrome (2023)
